argenx completes acquisition of Forte Biosciences
The deal brings the anti-CD122 antibody FB102 into argenx's immunology pipeline after a cash tender offer at $77.00 per share.
SEC filing
Latest
9 stories
Wednesday, September 16
Thursday, August 27
Monday, August 24
argenx opens Phase 1 bioequivalence trial comparing efgartigimod autoinjector to prefilled syringe
Wednesday, August 19
argenx registers Phase 2 trial of ARGX-121 in IgA nephropathy
Monday, August 17
argenx reports positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositis
The trial hit its primary endpoint in patients with IMNM and dermatomyositis, with argenx citing significant improvement over placebo at Week 52.
SEC filing
Wednesday, August 12
argenx posts ADAPT SERON Phase 3 results; registers new Phase 2 in Sjögren's neuropathy
Thursday, August 6
Halozyme posts record Q2 2026, raises full-year guidance on royalty growth
Five new ENHANZE and Hypercon collaborations signed through July, including deals with Vertex, GSK, Incyte and Oruka, push revenue and EBITDA guidance higher.
SEC filing
Tuesday, August 4
argenx registers Phase 3 trial of adimanebart in rare congenital myasthenic syndromes
Monday, July 27
argenx to acquire Forte Biosciences for $77 per share in cash
The immunology company will pay about $2.2 billion for Forte's anti-CD122 antibody FB102, tested in vitiligo and celiac disease.
SEC filing